Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleClinical Investigation

Predictive Value of Initial 18F-FLT Uptake in Patients with Aggressive Non-Hodgkin Lymphoma Receiving R-CHOP Treatment

Ken Herrmann, Andreas K. Buck, Tibor Schuster, Alexandra Junger, Hinrich A.Wieder, Nicolas Graf, Ingo Ringshausen, Martina Rudelius, Hans-Jürgen Wester, Markus Schwaiger, Ulrich Keller and Tobias Dechow
Journal of Nuclear Medicine May 2011, 52 (5) 690-696; DOI: https://doi.org/10.2967/jnumed.110.084566
Ken Herrmann
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andreas K. Buck
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tibor Schuster
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexandra Junger
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hinrich A.Wieder
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicolas Graf
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ingo Ringshausen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martina Rudelius
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hans-Jürgen Wester
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Markus Schwaiger
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ulrich Keller
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tobias Dechow
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    Transaxial views of 18F-FLT PET, helical CT, and 18F-FDG PET for 2 patients with DLBCL. (A) A 41-y-old man with retromandibular lymphoma showing intense 18F-FDG and 18F-FLT uptake in projection of retromandibular lymph node. This stage IA patient revealed PD under therapy. (B) A 40-y-old woman (stage IVA) with histologically proven lymphoma in right iliac bone and sacrum. 18F-FDG PET shows intensely increased uptake in right ilium and sacrum. Corresponding 18F-FLT PET images allow detection of increased asymmetric uptake in right ilium and sacrum despite high physiologic 18F-FLT uptake in proliferating bone marrow. Transaxial views of helical CT display osteodestruction of right ilium. Restaging after end of therapy revealed CR.

  • FIGURE 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2.

    Initial 18F-FLT uptake (SUVmean) in patients achieving CR vs. patients with PR or PD (P = 0.049; difference in median values, 2.5 [95% CI, 0.0–5.2]).

  • FIGURE 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3.

    Initial 18F-FLT uptake (SUVmean) in patients with IPI score lower than or equal to 2, compared with patients with IPI score greater than 2 (P = 0.012; difference in medians, 2.1 (95% CI, 0.5–3.7) (top). Trend analysis of initial 18F-FLT uptake (SUVmean) with IPI risk groups (Spearman ρ, +0.44, P < 0.001) (bottom).

  • FIGURE 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 4.

    (A) Martingale residual analysis of IPI score and risk of death. Solid lines depict smoothing spline function, with simultaneous 95% confidence bands. Three patients with lymphoma-associated death had IPI scores of 2, 4, and 4. Corresponding estimated hazard ratio per 1-point increment of IPI score was 1.43 (95% CI, 0.81–2.52, P = 0.22). (B) Martingale residual plots of overall survival and initial 18F-FLT uptake. Solid lines depict smoothing spline function, with simultaneous 95% confidence bands. Corresponding estimated hazard ratio per 1-point increment of 18F-FLT SUVmean was 1.03 (95% CI, 0.83–1.27, P = 0.80). Initial 18F-FLT uptake was significantly higher in 3 patients with lymphoma-associated death (mean, 11.1; range, 9.7–13.7) than in those with non–lymphoma-associated deaths (mean, 6.6; range, 4.5–7.5; P = 0.036) and in whole study cohort (mean, 7.3; P = 0.034).

Tables

  • Figures
    • View popup
    TABLE 1

    Histology of All Screened Lymphoma Patients (n = 70)

    Histologyn
    DLBCL64
    Follicular lymphoma grade I2
    Follicular lymphoma grade IIIB2
    Large cell anaplastic T-cell lymphoma2
    • View popup
    TABLE 2

    Characteristics of Eligible Patients (n = 66)

    CharacteristicValuePercentage
    Age (y)
     Median63
     Range26–82
    Stage (n)
     I1827
     II1015
     III69
     IV3249
    IPI score (n)
     0/12436
     21726
     31421
     41015
     512
    Response (n)
     CR5583
     PR35
     PD46
     NA46
    18F-FLT uptake (SUVmean)
     Mean7.3
     SD3.3
     Median6.9
     Range1.0–18.2
    • Response could not be assessed in 4 patients (NA) because they had died early or were lost to follow-up. In 1 patient, IPI score could not be determined.

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 52 (5)
Journal of Nuclear Medicine
Vol. 52, Issue 5
May 1, 2011
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Predictive Value of Initial 18F-FLT Uptake in Patients with Aggressive Non-Hodgkin Lymphoma Receiving R-CHOP Treatment
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Predictive Value of Initial 18F-FLT Uptake in Patients with Aggressive Non-Hodgkin Lymphoma Receiving R-CHOP Treatment
Ken Herrmann, Andreas K. Buck, Tibor Schuster, Alexandra Junger, Hinrich A.Wieder, Nicolas Graf, Ingo Ringshausen, Martina Rudelius, Hans-Jürgen Wester, Markus Schwaiger, Ulrich Keller, Tobias Dechow
Journal of Nuclear Medicine May 2011, 52 (5) 690-696; DOI: 10.2967/jnumed.110.084566

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Predictive Value of Initial 18F-FLT Uptake in Patients with Aggressive Non-Hodgkin Lymphoma Receiving R-CHOP Treatment
Ken Herrmann, Andreas K. Buck, Tibor Schuster, Alexandra Junger, Hinrich A.Wieder, Nicolas Graf, Ingo Ringshausen, Martina Rudelius, Hans-Jürgen Wester, Markus Schwaiger, Ulrich Keller, Tobias Dechow
Journal of Nuclear Medicine May 2011, 52 (5) 690-696; DOI: 10.2967/jnumed.110.084566
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE STATEMENT
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • 18F-FLT PET/CT as a Prognostic Imaging Biomarker of Disease-Specific Survival in Patients with Primary Soft-Tissue Sarcoma
  • Prospective Study of 3'-Deoxy-3'-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma
  • Early Determination of Prognosis by Interim 3'-Deoxy-3'-18F-Fluorothymidine PET in Patients with Non-Hodgkin Lymphoma
  • [18F]-FLT Positron Emission Tomography Can Be Used to Image the Response of Sensitive Tumors to PI3-Kinase Inhibition with the Novel Agent GDC-0941
  • A Pilot Study to Evaluate 3'-Deoxy-3'-18F-Fluorothymidine PET for Initial and Early Response Imaging in Mantle Cell Lymphoma
  • How Many PET Tracers Do We Need?
  • Google Scholar

More in this TOC Section

  • First-in-Human Study of 18F-Labeled PET Tracer for Glutamate AMPA Receptor [18F]K-40: A Derivative of [11C]K-2
  • Detection of HER2-Low Lesions Using HER2-Targeted PET Imaging in Patients with Metastatic Breast Cancer: A Paired HER2 PET and Tumor Biopsy Analysis
  • [11C]Carfentanil PET Whole-Body Imaging of μ-Opioid Receptors: A First in-Human Study
Show more Clinical Investigation

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire